 |
Chameleon Biosurfaces |
Chameleon Biosurfaces is developing the next generation of polymer coatings for implantable medical devices, such as drug eluting stents. The polymers provide beneficial features that enhance implants performance. Beneficial features can include minimising adverse events that can occur in patients after devices have been implanted, and features that help clinicians in the successful deployment of implants during operations. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: October 2005 | www.chameleonbio.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Crescendo Biologics |
Crescendo Biologics is developing two proprietary platforms for biological therapeutics from the Babraham Institute: ribosome display for the optimization of antibodies and a transgenic mouse which produces heavy chain only antibodies. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: June 2008 | www.crescendobiologics.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Cytox |
Cytox is developing a diagnostic test and therapeutic cures for Alzheimer's Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases. |
Funded by the Advantage Growth Fund
|
| 1st Investment: December 2006 | www.cytoxgroup.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
L3 Technology |
L3T is addressing the $10bn global market for cholesterol testing, using technology from a leading team of scientists based at STFC's Daresbury Laboratory in Cheshire to develop a diagnostic tool for full spectrum cholesterol testing at the point of care.
A 2004 RSF pathfinder funded some confirmatory research to back up claims in a patent, with further investment since taking the total to £242,000. The company has recently raised a further £1.7m from angels and venture funds and expects to have a fully functioning device within the next six to twelve months.
|
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2004 | www.l3technology.co.uk |
| Sector: Medical / Biotechnology |
|
|
|
 |
Microvisk |
Microvisk has a unique approach to the measurement of the viscosity of blood and other fluid, based on CCLRC's considerable expertise in its Central Microfabrication Facility. The patented technology involves the spatial movement of microfabricated thermal bimorohs - bimetallic strips - which is converted into an electric signal using the piezo electric effect. Microvisk's technology can revolutionise the diagnostic market by simplifying the most common coagulation tests (those that are critical to the monitoring of any patient at risk from blood clotting and heart problems) and by providing instant POC and NP testing and analysis. |
Funded by the Advantage Growth Fund and the Rainbow Seed Fund
|
| 1st Investment: January 2004 | www.microvisk.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Novacta |
Novacta is a drug discovery and development company using pathway engineering and chemistry to optimise the activity of natural products for the treatment of infectious diseases. The company combines proprietary technologies from the world-renowned Actinomycete group of the John Innes Centre, Norwich with the know-how of a highly experienced team drawn from major pharmaceutical companies and the biotechnology industry.
|
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2005 | www.novactabio.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Cellcentric |
| Epigenetics is the study of the control mechanisms that sit on top of genes and guide the function and fate of individual cells. The field is expected to radically change traditional approaches to many healthcare areas, including cancer therapeutics and tissue regeneration. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2005 | www.cellcentric.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
ProKyma |
ProKyma is based on Dstl's proprietary ultrasound technology for manipulating particles.
Sensitive detection methods are limited by the purity of the starting material. Techniques are available to purify and concentrate biological specimens but these methods are often labour intensive or only partly effective. Major improvements in analysing biological samples such as bacteria, cells and DNA require improved sample preparation. ProKyma's Sonic Separation technology provides a means for concentrating and purifying cells or micro-organisms. Sonic Separation can also be used to isolate or analyse cell aggregates, for example in blood grouping and serology. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2006 | www.prokyma.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Aitua |
| Aitua provides critical support to new bioventures during the first stages of the technology-to-business translation process. It works closely with entrepreneurs and scientists to create and nurture emerging companies from world-class science and technology deriving from the Babraham Research Campus and other life science clusters in the UK. It provides seed and early stage funding, injects specific expertise and provides access to services and facilities. This reduces cash-burn during the formative years and so enables companies to get off the ground. Aitua has a unique offering designed to accelerate the formation of quality, venture-ready early-stage companies. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2006 | www.aitua.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Procarta Biosystems |
Procarta Biosystems is a spin-out from one of Europe's leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).
Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2008 | www.procartabio.com |
| Sector: Medical / Biotechnology |
|
|
|
 |
Colbalt Light Systems |
Cobalt Light Systems provides new and proprietary analysis techniques using Raman spectroscopy for high throughput non-invasive pharmaceutical analysis of tablets, capsules, powders etc. incuding chemical and polymorph/amorphous content. A second technique involves the rapid non-invasive analysis of materials below layers e.g. materials characterisation through coloured and opaque containers for pharmaceuticals/security uses, tissue analysis through skin and academic research. |
Funded by the Rainbow Seed Fund
|
| 1st Investment: November 2005 | www.cobaltlight.com |
| Sector: Medical / Biotechnology |
|
|
|
.jpg) |
Claresys Limited |
Claresys Ltd has developed a Compact Optically Scanning Enhanced (COSE) pinhole camera. The COSE Camera Lens has an independent internal zoom and internal pan & tilt capability, using novel optical component arrangements, where the camera remains stationary. With no external moving parts it is possible to scan onto any target subject within the instantaneous field of view of the lens (up to 125O) and then zoom in onto it. Its applications cover surveillance, oil & gas exploration and other hazardous environments.
|
Funded by the Rainbow Seed Fund
|
| 1st Investment: January 2009 | www.claresys.com/Nindex.html |
| Sector: Medical / Biotechnology |
|
|
|
 |
Anaxsys Technology |
Anaxsys Technology, which is based at Keele University in Staffordshire, is a medical technology company developing a suite of devices which allow the diagnosis and monitoring of a variety of respiratory diseases by analysing the humidity profile of human breath. With long term potential to screen for lung cancer and monitoring the treatment of asthma, its first product will be a respiratory rate monitor for use in the care of patients recovering from operations. |
Funded by the Early Advantage Fund
|
| 1st Investment: February 2010 | www.anaxsys.co.uk |
| Sector: Medical / Biotechnology |
|
|
|
Medical / Biotechnology
